You just read:

Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion

News provided by

Blueprint Medicines Corporation

Jul 27, 2017, 06:35 ET